Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Sporadic inclusion body myositis (sIBM) presents with a characteristic ... polymyositis to a controlled study that investigated treatment with high-dose intravenous immunoglobulin.

Nation Radio’s Steve Power has revealed on Facebook he has been diagnosed with inclusion ... the body's immune system turns against its own muscles and damages tissue. While there is no cure ...

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

sIBM is a complex disorder, the underlying cause of which is unclear. The observation that the intact muscle fibers are invaded by T lymphocytes, whereas the vacuolated fibers lack T-cell ...